NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Net Income Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual net income in 2023 was -22.38 Million CAD , down -23.61% from previous year.
NervGen Pharma Corp.'s latest quarterly net income in 2024 Q2 was -7.8 Million CAD , down -240.26% from previous quarter.
NervGen Pharma Corp. reported an annual net income of -18.1 Million CAD in 2022, down -43.22% from previous year.
NervGen Pharma Corp. reported an annual net income of -12.64 Million CAD in 2021, down -13.11% from previous year.
NervGen Pharma Corp. reported a quarterly net income of -7.8 Million CAD for 2024 Q2, down -240.26% from previous quarter.
NervGen Pharma Corp. reported a quarterly net income of -4.76 Million CAD for 2023 Q2, up 1.71% from previous quarter.

Annual Net Income Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Net Income of NervGen Pharma Corp. (2023 - 2017)

Year	Net Income	Net Income Growth
2023	-22.38 Million CAD	-23.61%
2022	-18.1 Million CAD	-43.22%
2021	-12.64 Million CAD	-13.11%
2020	-11.17 Million CAD	-15.62%
2019	-9.66 Million CAD	-611.59%
2018	-1.35 Million CAD	-11399.9%
2017	-11.81 Thousand CAD	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-2.3 Million CAD	73.28%
2024 Q2	-7.8 Million CAD	-240.26%
2023 Q2	-4.76 Million CAD	1.71%
2023 Q1	-4.84 Million CAD	6.51%
2023 FY	-22.38 Million CAD	-23.61%
2023 Q4	-8.6 Million CAD	-100.08%
2023 Q3	-4.3 Million CAD	9.65%
2022 Q1	-4.98 Million CAD	-20.21%
2022 FY	-18.1 Million CAD	-43.22%
2022 Q4	-5.18 Million CAD	-29.22%
2022 Q3	-4.01 Million CAD	36.86%
2022 Q2	-6.35 Million CAD	-27.43%
2021 FY	-12.64 Million CAD	-13.11%
2021 Q4	-4.14 Million CAD	-15.21%
2021 Q3	-3.59 Million CAD	-31.7%
2021 Q2	-2.73 Million CAD	-21.6%
2021 Q1	-2.24 Million CAD	50.84%
2020 Q3	-2.13 Million CAD	18.63%
2020 FY	-11.17 Million CAD	-15.62%
2020 Q1	-1.85 Million CAD	35.61%
2020 Q2	-2.62 Million CAD	-41.01%
2020 Q4	-4.57 Million CAD	-114.29%
2019 Q4	-2.88 Million CAD	-23.87%
2019 Q2	-1.52 Million CAD	49.53%
2019 Q1	-3.02 Million CAD	-293.45%
2019 Q3	-2.33 Million CAD	-52.87%
2019 FY	-9.66 Million CAD	-611.59%
2018 Q2	-64.35 Thousand CAD	-505.7%
2018 Q3	-515.54 Thousand CAD	-701.15%
2018 Q4	-767.96 Thousand CAD	-48.96%
2018 FY	-1.35 Million CAD	-11399.9%
2018 Q1	-10.62 Thousand CAD	0.0%
2017 FY	-11.81 Thousand CAD	0.0%

Peer Net Income Comparison of NervGen Pharma Corp.

Name	Net Income	Net Income Difference
Arch Biopartners Inc.	-3.32 Million CAD	-572.797%
Covalon Technologies Ltd.	-4.46 Million CAD	-401.729%
Hemostemix Inc.	-2.5 Million CAD	-794.53%
Universal Ibogaine Inc.	-10.49 Million CAD	-113.24%
Kane Biotech Inc.	-5.03 Million CAD	-344.61%
MedMira Inc.	-2.67 Million CAD	-736.509%
Marvel Biosciences Corp.	-2.29 Million CAD	-876.793%
XORTX Therapeutics Inc.	-2.85 Million CAD	-682.764%